Cover Image
Market Research Report

Diabetic Gastroparesis - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 229780
Published Content info 72 Pages
Delivery time: 1-2 business days
Price
Back to Top
Diabetic Gastroparesis - Pipeline Review, H1 2020
Published: February 28, 2020 Content info: 72 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2020, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 3, 6 and 1 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11987IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Gastroparesis - Overview
  • Diabetic Gastroparesis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Diabetic Gastroparesis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Diabetic Gastroparesis - Companies Involved in Therapeutics Development
  • AlfaSigma SpA
  • Allergan Plc
  • Atlantic Healthcare Plc
  • Bird Rock Bio Inc
  • Censa Pharmaceuticals Inc
  • CinRx Pharma LLC
  • ETX Pharma Inc
  • Evoke Pharma Inc
  • Johnson & Johnson
  • Takeda Pharmaceutical Co Ltd
  • Vanda Pharmaceuticals Inc
  • Diabetic Gastroparesis - Drug Profiles
  • CIN-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CNSA-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ETX-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • metoclopramide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nimacimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • prucalopride succinate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • relamorelin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • renzapride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-906 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tradipitant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • velusetrag - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Diabetic Gastroparesis - Dormant Projects
  • Diabetic Gastroparesis - Discontinued Products
  • Diabetic Gastroparesis - Product Development Milestones
  • Featured News & Press Releases
  • Jan 21, 2020: FDA accepts Evoke Pharma's NDA resubmission for Gimoti
  • Dec 20, 2019: Evoke resubmits Gimoti new drug application to FDA
  • Sep 17, 2019: Evoke Pharma completes manufacturing of commercial scale registration batches of Gimoti
  • Aug 08, 2019: Evoke Pharma to resubmit Gimoti NDA based on FDA Meeting minutes and announces second quarter 2019 financial results
  • Jun 27, 2019: Evoke Pharma requests Type A FDA meeting to plan for resubmission of Gimoti NDA
  • May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
  • Apr 02, 2019: Evoke Pharma receives complete response letter and recommendations to address deficiencies from FDA for Gimoti NDA
  • Jan 07, 2019: Evoke Pharma signs commercial and financial agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners
  • Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis
  • Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018
  • Aug 16, 2018: Evoke Pharma's Gimoti NDA Accepted for FDA Review
  • Jun 04, 2018: Evoke Announces FDA Submission of New Drug Application for Gimoti
  • May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
  • May 10, 2018: Evoke Granted Gender Specific Patent for Gimoti in Mexico
  • Apr 30, 2018: Evoke Granted First Gender Specific Patent for Gimoti
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Gastroparesis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Diabetic Gastroparesis - Pipeline by AlfaSigma SpA, H1 2020
  • Diabetic Gastroparesis - Pipeline by Allergan Plc, H1 2020
  • Diabetic Gastroparesis - Pipeline by Atlantic Healthcare Plc, H1 2020
  • Diabetic Gastroparesis - Pipeline by Bird Rock Bio Inc, H1 2020
  • Diabetic Gastroparesis - Pipeline by Censa Pharmaceuticals Inc, H1 2020
  • Diabetic Gastroparesis - Pipeline by CinRx Pharma LLC, H1 2020
  • Diabetic Gastroparesis - Pipeline by ETX Pharma Inc, H1 2020
  • Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2020
  • Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H1 2020
  • Diabetic Gastroparesis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Diabetic Gastroparesis - Pipeline by Vanda Pharmaceuticals Inc, H1 2020
  • Diabetic Gastroparesis - Dormant Projects, H1 2020
  • Diabetic Gastroparesis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Diabetic Gastroparesis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Back to Top